The impact of bioprospecting for the discovery of new drugs

Lana Grasiela Alves Marques
Jose de Brito Vieira Neto
Sarah Leyenne Alves Sales
Pedro Mikael da Silva Costa
Celina de Jesus Guimarães
Mariana Palmeira Manso
João Victor de Melo Pereira
Claudia do Ó Pessoa

    Lana Grasiela Alves Marques

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil

    Graduated in Bachelor in Chemistry with Technological Attribution from the Federal University of Piauí (2001) and Master in Chemistry from the Federal University of Piauí (2004), Ph.D. in Biotechnology by Northeast Biotechnology Network (RENORBIO), Federal University of Ceará, UFC, with 6-month sandwich period at World Intellectual Property Organization ? WIPO Geneva/Suisse. He developed internship work at Instituto Superior Técnico de Lisboa in the Area of ​​Technology Transfer (TT @ IST), Intellectual Property Nucleus (NPI) (2012). He has experience in Chemistry, with an emphasis on Inorganic. He works on the following topics: Intellectual Property, Technological Prospecting. During the internship at the NPI, it was possible to obtain knowledge of the Intellectual Property Law of Portugal and the models of the Regulation of Ownership Agreement; Collaboration Protocol; Intellectual Property Protection Clauses for Research Projects in Consortium of Instituto Superior Técnico de Lisboa (IST). He visited the Biotechnology Park of Cantanhede-Portugal, the BIOCANT PARK. At BIOCANT he participated in the Clustering in Biotechnology Workshop promoted by the Association of Portuguese Business and Innovation Centers / BICS. In 2011, he participated in the Portugal Mission of the NIT-NE REDE. The objective of the Portugal Mission was to get to know the Technology Transfer Networks that included the Academic Sector of Portugal, among the institutions visited during the mission: Higher Institute of Economics and Management / UTL; Instituto Superior Técnico Area of ​​Technology Transfer ? TT@IST; Associação Universidade Empresa para o Desenvolvimento - TECMINHO / Universidade do Minho; Business Association for Innovation - COTEC PORTUGAL; University of Porto - UPIN; Technology Transfer Unit - UATEC / University of Aveiro; Instituto Pedro Nunes - IPN / University of Coimbra. He has additional training in Patent and Patent Writing in Biotechnology by the National Institute of Industrial Property of Portugal (INPI-PT), Project Management; Technological Prospecting; Intellectual Property and Innovation; Negotiation, Marketing and Contracts; Technological Assessment; Structuring of Technological Innovation Centers. All these courses are coordinated by the National Institute of Industrial Property (INPI) Brazil and the World Intellectual Property Organization (WIPO - Geneva). Experience and training in software that carry out technological and scientific prospecting in worldwide databases.

    Jose de Brito Vieira Neto

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil

    Graduated in Biological Sciences at the Federal University of Ceará and study abroad period through the Science Without Borders program at the University of Western Australia. Currently working at the Experimental Oncology Laboratory of the Federal University of Ceará, as a PhD student doing research on the development of a immunoliposome for the treatment of prostate cancer. Previously I worked in the Laboratory of Plant Cell Biology and as a monitor in the unit of Cell Biology.

    Sarah Leyenne Alves Sales

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil

    Biomedical, currently a Master's student in the Postgraduate Program in Pharmacology at the Federal University of Ceará (UFC). Graduated from Centro Universitário Unifanor/Wyden, during her graduation she joined the Scientific and Technological Initiation Program (PICT) at UniFanor/Wyden, as a scientific initiation student, she was monitor of Clinical Immunology (practical), Basic Hematology (theoretical) and Clinical Hematology (practical), he was also a Member of the Scientific Development Center (CDC) & was part of the Academic Center of Biomedicine (CA) of the University Center of Unifanor/Wyden, during this period he was also part of the Laboratory of Studies in Physio-Pharmacology of the Gastrointestinal System ( LEFFAG) and Experimental Oncology Laboratory (LOE), As a scientific initiation student, both at the Federal University of Ceará - UFC, and who always seeks to be involved in matters of scientific importance, acquiring and passing on knowledge.

    Pedro Mikael da Silva Costa

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil

    Bachelor of Pharmacy from the Federal University of Ceará (2018). He is currently a PhD candidate at Rede Nordeste de Biotecnologia (RENORBIO) under the supervision of Professor Cláudia do Ó Pessoa (2019-2022) and Co-supervision of Dr Carlos Roberto Paier. He worked with antimicrobial activity of natural products. Experience with cloning, transformation, expression, purification and characterization of recombinant metalloproteins. He is currently carrying out biophysical studies of protein-small molecule interaction to validate antimitotic targets.

    Celina de Jesus Guimarães

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil

    Graduated in Pharmacy from the Federal University of Amazonas (2005) and Master's degree in Biotechnology and Amazon Natural Resources from the State University of Amazonas (2010). He has experience in the field of Pharmacy, with an emphasis on Hospital Pharmacy and Oncology. As a hospital pharmacist at the Amazonas Oncology Control Center Foundation for 14 years, she has experience in implementing new services and routines, such as a pharmaceutical office to care for cancer patients. She is currently a PhD student in the Postgraduate Program in Pharmacology, linked to the Department of Physiology and Pharmacology of the Faculty of Medicine, Federal University of Ceará. It has been developing research in the field of Pharmacology, with a focus on Experimental Oncology and an emphasis on the development of Nanoformulations for pre-clinical trials, which started in 2019.

    Mariana Palmeira Manso

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil

    Student in Biological Sciences at the Federal University of Ceará. She is currently a Technological Development Scholar from the Empreende UFC program at the startup Biotech4Life, coordinated by Professors Dr. Denise Cavalcante Hissa and Dr. Maria Vânia Maciel Melo. In addition, she works at the Laboratory of Experimental Oncology (LOE) in the field of Pharmacology, under the guidance of Professor Dr. Cláudia do Ó Pessoa. She is one of 4 Brazilian students selected for the Study of the US Institutes (SUSIs) 2021 program at the University of Washington, Seattle, whose aim is to promote education, community projects and outreach through multicultural activities and environments. She is a member of the Professor Valdinar Custódio Academic Directory of the Biological Sciences course and also writes for the Jornal O Clima, relating scientific dissemination, biology and the environment. She works as a volunteer in the organizations Enactus UFC, in the Cânio Verde project, in which she promotes the construction of eco-cesspits in cities in Ceará, and AIESEC Fortaleza, encouraging voluntary exchanges.

    João Victor de Melo Pereira

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil

    He is currently a student at the Federal University of Ceará in the pharmacy course. Has experience in the area of Biochemistry, works in the extraction of proteins, carbohydrates and lectins for pharmacological use, former member of the Carbohydrates and Lectins Laboratory (CARBOLEC) in the following subjects: phycobiliprotein, photosynthetic pigments, anxiety, depression and inflammation. Member of the Experimental Oncology Laboratory (LOE) and working testing drugs to observe their antitumor capacity. Former member of the Pharmaceutical Care Center with emphasis on primary health care and working at UFC's Ipharma Consultoria Farmacêutica Júnios.

    Claudia do Ó Pessoa

    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil.

    CNPq Research Productivity Scholarship - Level 1B - CA BI - Biotechnology. Doctor in Pharmacology, UFC. Experience in the field of Pharmacology, emphasis on Cytotoxic Activity, Angiogenesis, Antitumor, Genotoxicity and Toxicity of natural products in vitro and in vivo, from plants, marine animals and microorganisms. It develops prospecting and bioprospecting activities of natural and synthetic products for anticancer activity, using automated tests: High Throughput Screening (HTS).

Keywords

Anticancer
Screening
Biodiversity
Bioactive
Bioprospecting

Abstract

The use of natural products in the development of new drugs has been widely discussed in the last 50 years. In this sense, the biodiversity of several countries significantly influences the discovery of new bioactive molecules, such as the chemotherapeutic agents of natural origin vinblastine and Taxol. Bioprospecting, which refers to the collection of new plant species to be tested in screening models and subsequently in analytical techniques, generates several molecules whose activities may configure potential biological actions in the treatment of different diseases, such as cancer. Under this perspective, the present work aims to relate the screening models High Content Screening, High Throughput Screening and Virtual Screening, in the discovery of new molecules. In addition, comparatively analyzing institutions, legislations and financial investments in the study and development of natural’s products according to their biodiversity. It was concluded that, although there are efforts for the use of biodiversity in the advancement of science, they still have several difficulties, especially Brazil, which has not presented an expressive program or contract in bioprospecting as the other nations mentioned.

References

  1. Soejarto D, Fong H, Tan G, Zhang H, Ma C, Franzblau S et al. Ethnobotany/ethnopharmacology and mass bioprospecting: Issues on intellectual property and benefit-sharing. J ethnopharmacol. 2005; 100(1-2): 15-22. [CrossRef] [PubMed].
  2. Artuso A. Bioprospecting, benefit sharing, and biotechnological capacity building. World Develop. 2002; 30(8): 1355-68. [CrossRef].
  3. Feinsilver JM. Prospección de la biodiversidad: potencialidades para los países en desarrollo. Rev la CEPAL. 60: 1996. [Link].
  4. Saccaro Jr NL. A regulamentação de acesso a recursos genéticos e repartição de benefícios: disputas dentro e fora do Brasil. Amb Soc. 2011; 14(1): 229-44. [CrossRef] [Link].
  5. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020; 83(3): 770-803. [CrossRef] [PubMed].
  6. McCloud TG. High throughput extraction of plant, marine and fungal specimens for preservation of biologically active molecules. Molecules. 2010; 15(7): 4526-63. [CrossRef] [PubMed].
  7. Thornburg CC, Britt JR, Evans JR, Akee RK, Whitt JA, Trinh SK et al. NCI program for natural product discovery: a publicly-accessible library of natural product fractions for high-throughput screening. ACS Chem Biol. 2018; 13(9): 2484-97. [CrossRef] [PubMed].
  8. Zanella F, Lorens JB, Link W. High content screening: seeing is believing. Trends Biotechnol. 2010; 28(5): 237-45.[CrossRef] [PubMed].
  9. Gallego-Jara J, Lozano-Terol G, Sola-Martínez RA, Cánovas-Díaz M, de Diego Puente T. A compressive review about taxol®: History and future challenges. Molecules. 2020; 25(24): 5986. [CrossRef] [PubMed].
  10. Demain AL, Vaishnav P. Natural products for cancer chemotherapy. Microb Biotechnol. 2011; 4(6): 687-99. [CrossRef] [PubMed].
  11. Starkuviene V, Pepperkok R. The potential of highâ€content highâ€throughput microscopy in drug discovery. British J Pharmacol. 2007; 152(1): 62-71. [CrossRef] [PubMed].
  12. Zock JM. Applications of high content screening in life science research. Comb Chem High Throughput Screen. 2009; 12(9): 870-6. [CrossRef] [PubMed].
  13. Lucas DM, Still PC, Perez LB, Grever MR, Kinghorn AD. Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets. 2010; 11(7): 812-22. [CrossRef] [PubMed].
  14. Newman D. Screening and identification of novel biologically active natural compounds. F1000Research. 2017; 6. [CrossRef] [PubMed].
  15. Voigt W. Sulforhodamine B assay and chemosensitivity. In: Blumenthal RD (eds) Chemosensitivity: Methods in Molecular Medicineâ„¢, Humana Press. 2005; 110: 39-48. ISBN: 978-1-58829-345-9. [CrossRef] [Link].
  16. Paull K, Shoemaker R, Hodes L, Monks A, Scudiero D, Rubinstein L et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. JNCI: J Nat Cancer Inst. 1989; 81(14): 1088-92. [CrossRef] [PubMed].
  17. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017; 17(2): 93-115. [Link].
  18. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48(3): 589-601. [Link].
  19. Shou WZ. Current status and future directions of high-throughput ADME screening in drug discovery. J Pharmac Analysis. 2020; 10(3): 201-8. [CrossRef] [PubMed].
  20. Aseervatham J. Cytoskeletal remodeling in cancer. Biology. 2020; 9(11): 385.[CrossRef] [PubMed].
  21. Li S, Xia M. Review of high-content screening applications in toxicology. Arch Toxicol. 2019; 93(12): 3387-96. [Link].
  22. Singh S, Carpenter AE, Genovesio A. Increasing the content of high-content screening: an overview. J Biomol Screening. 2014; 19(5): 640-50. [CrossRef] [PubMed].
  23. Radio NM, Mundy WR. Developmental neurotoxicity testing in vitro: models for assessing chemical effects on neurite outgrowth. Neurotoxicol. 2008; 29(3): 361-76. [CrossRef] [PubMed].
  24. Ma Z, Cao X, Guo X, Wang M, Ren X, Dong R et al. Establishment and validation of an in vitro screening method for traditional Chinese medicine-induced nephrotoxicity. Evidence-Based Compl Alter Med. 2018; 2018. [CrossRef].
  25. Carpenter AE. Image-based chemical screening. Nat Chem Biol. 2007; 3(8): 461-5. [CrossRef] [PubMed].
  26. Justice BA, Badr NA, Felder RA. 3D cell culture opens new dimensions in cell-based assays. Drug Discov Today. 2009; 14(1-2): 102-7. [CrossRef] [PubMed].
  27. Wenzel C, Riefke B, Gründemann S, Krebs A, Christian S, Prinz F et al. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Experim Cell Res. 2014; 323(1): 131-43. [CrossRef] [PubMed].
  28. William Downey JH. Adoption of high content screening at High Throughput Screening Laboratories –Drug Discovery World (DDW)â€. Drug Discov World Spr. 2013. [Link].
  29. Xu Y, Cai C, Wang S, Lai L, Pei J. Efficient molecular encoders for virtual screening. Drug Discov Today: Technol. 2020. [CrossRef] [PubMed].
  30. Kumar V, Krishna S, Siddiqi MI. Virtual screening strategies: Recent advances in the identification and design of anti-cancer agents. Methods. 2015; 71: 64-70. [CrossRef] [PubMed].
  31. Banegas-Luna A-J, Cerón-Carrasco JP, Pérez-Sánchez H. A review of ligand-based virtual screening web tools and screening algorithms in large molecular databases in the age of big data. Fut Med Chem. 2018; 10(22): 2641-58. [CrossRef] [PubMed].
  32. Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. Inter J Mol Sci. 2019; 20(18): 4331. [CrossRef] [PubMed].
  33. Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules. 2015; 20(7): 13384-421. [CrossRef] [PubMed].
  34. Miles JA, Ross BP. Recent Advances in Virtual Screening for Cholinesterase Inhibitors. ACS Chem Neurosci. 2020; 12(1): 30-41. [CrossRef] [PubMed].
  35. Huang M, Lu J-J, Ding J. Natural products in cancer therapy: Past, present and future. Nat Prod Bioprospec. 2021: 1-9. [Link].
  36. Berlinck RG, Borges WdS, Scotti MT, Vieira PC. A química de produtos naturais do Brasil do século XXI. Quím Nova. 2017; 40: 706-10. [CrossRef].
  37. Astolfi Filho S, Silva CGNd, Bigi MdFMA. Bioprospecção e biotecnologia. Parc Estrat. 2015; 19(38): 45-80. [Link].
  38. Aldewachi H, Al-Zidan RN, Conner MT, Salman MM. High-throughput screening platforms in the discovery of novel drugs for neurodegenerative diseases. Bioengineering. 2021; 8(2): 30. [CrossRef] [PubMed].
  39. Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Front Pharmacol. 2020; 10: 1614. [CrossRef] [PubMed].
  40. Mesquita JL. Biodiversidade, saiba quais são os países campeões 2019. Acesso em: 8/05/2021. Available from: [Link].
  41. Garraffoni ARS, Amaral ACZ, Marques AC, Camargo AFM, Joly CA et al. Brazilian Biodiversity Research: A Promising Future. Biota-Fapesp Program. São Paulo Research Foundation (FAPESP). 2017. [Link].
  42. Prip C, Rosendal GK, Andresen S, Walløe M. The Australian ABS Framework: A Model Case for Bioprospecting? Environment. 2014; 15(8A): 42. [Link].
  43. Förster JJ, Downsborough L, Biber-Freudenberger L, Mensuro GK, Börner J. Exploring criteria for transformative policy capacity in the context of South Africa’s biodiversity economy. Policy Sci. 2021; 54(1): 209-37. [Link].
  44. Abdalla MA, McGaw LJ. Bioprospecting of South African plants as a unique resource for bioactive endophytic microbes. Fron Pharmacol. 2018; 9: 456. [CrossRef] [PubMed].
  45. Stolfer EJ. Bioprospecting legislation in the united states: what we are doing, what we are not doing, and what should we do next. Clev State Law Rev. 2017; 65(1): 101. [Link].
  46. da Rocha MCA, de Araújo LEB. Biodiversidade brasileira: biopirataria e a proteção dos conhecimentos tradicionais. Rev Direito UFMS. 2018; 4(1). [CrossRef].
  47. Pereira AM, Silveira JMFJ, Lima DALL (editors). Regulamentação Nacional e Internacional para Acordos de Bioprospecção e Conhecimento Tradicional. VIII Encontro da Sociedade Brasileira de Economia Ecológica; 2009; Cuiabá, Mato Grosso. [CrossRef].
  48. de França E, Vasconcellos AG. Patentes de fitoterápicos no Brasil: uma análise do andamento dos pedidos no período de 1995-2017. Cad Ciên Tecnol. 2019; 35(3): 329-59. [CrossRef].
  49. Machado VNA. Participação do Aché na Internacionalização da Indústria Farmacêutica. Facto. 2019; 13(61): 28-9. [Link].
  50. Rodrigues A. Centro Biotecnológico da Amazônia será transformado em fundação. 2019 09 mai. 2021. Available from: [Link].
  51. Marques LG, Santos MR, Raffo J, Pessoa C. Redes de Bioprospecção no Brasil: cooperação para o desenvolvimento tecnológico. RDE - Rev Desenv Econ. 2014; 15(28). [CrossRef].
  52. Ryan MP. Patent incentives, technology markets, and public-private bio-medical innovation networks in Brazil. World Development. 2010; 38(8): 1082-93. [CrossRef].
  53. Ragavan S. New paradigms for protection of biodiversity. J Intellect Prop Rights. 2008; 13(13): 514. [Link].
  54. Buenz EJ, Schnepple DJ, Bauer BA, Elkin PL, Riddle JM, Motley TJ. Techniques: bioprospecting historical herbal texts by hunting for new leads in old tomes. Trends Pharmacol Sci. 2004; 25(9): 494-8. [CrossRef] [PubMed].
  55. Calixto J. Biopirataria: a diversidade biologica na mira da industria farmaceutica A antiga pirataria-o saque de navios mercantes em alto-mar-foi substituida, nos tempos atuais, em que a biodiversidade tornou-se uma grande riqueza, por outro tipo de saque. Ciên Hoje. 2000: 36. [Link].
  56. Christie M, Hanley N, Warren J, Murphy K, Wright R, Hyde T. Valuing the diversity of biodiversity. Ecol Econ. 2006; 58(2): 304-17. [CrossRef].
  57. Arunachalam V, John J, Kari V. Dendrimers, Conjugates and Methods Thereof. Centre For Biosep Technol. 2014. [Link].
PDF (Portuguese)
HTML (Portuguese)
Save bookmark

Author(s)

  • Lana Grasiela Alves Marques
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil
  • Jose de Brito Vieira Neto
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil
  • Sarah Leyenne Alves Sales
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil
  • Pedro Mikael da Silva Costa
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil
  • Celina de Jesus Guimarães
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil
  • Mariana Palmeira Manso
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil
  • João Victor de Melo Pereira
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil
  • Claudia do Ó Pessoa
    Federal University of Ceará (UFC), Health Sciences Center, Department of Physiology and Pharmacology. Rua Coronel Nunes de Melo, 1127, Rodolfo Teófilo, CEP 60430-275, Fortaleza, CE, Brazil.

Categories

Metrics

  • Article viewed 386 time(s)

How to Cite

1.
The impact of bioprospecting for the discovery of new drugs. Rev Fitos [Internet]. 2022 Mar. 4 [cited 2024 Nov. 26];16(Supl. 2):293-314. Available from: https://revistafitos.far.fiocruz.br/index.php/revista-fitos/article/view/1313
Crossref
Scopus
Google Scholar
Europe PMC

1. DIREITOS CEDIDOS - A cessão total não exclusiva, permanente e irrevogável dos direitos autorais patrimoniais não comerciais de utilização de que trata este documento inclui, exemplificativamente, os direitos de disponibilização e comunicação pública da OBRA, em qualquer meio ou veículo, inclusive em Repositórios Digitais, bem como os direitos de reprodução, exibição, execução, declamação, recitação, exposição, arquivamento, inclusão em banco de dados, preservação, difusão, distribuição, divulgação, empréstimo, tradução, dublagem, legendagem, inclusão em novas obras ou coletâneas, reutilização, edição, produção de material didático e cursos ou qualquer forma de utilização não comercial.

2. AUTORIZAÇÃO A TERCEIROS - A cessão aqui especificada concede à FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ o direito de autorizar qualquer pessoa – física ou jurídica, pública ou privada, nacional ou estrangeira – a acessar e utilizar amplamente a OBRA, sem exclusividade, para quaisquer finalidades não comerciais, nos termos deste instrumento.

3. USOS NÃO COMERCIAIS - Usos não comerciais são aqueles em que a OBRA é disponibilizada gratuitamente, sem cobrança ao usuário e sem intuito de lucro direto por parte daquele que a disponibiliza e utiliza.

4. NÃO EXCLUSIVIDADE - A não exclusividade dos direitos cedidos significa que tanto o AUTOR como a FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ ou seus autorizados poderão exercê-los individualmente de forma independente de autorização ou comunicação, prévia ou futura.

5. DIREITOS RESERVADOS - São reservados exclusivamente ao(s) AUTOR(es) os direitos morais sobre as obras de sua autoria e/ou titularidade, sendo os terceiros usuários responsáveis pela atribuição de autoria e manutenção da integridade da OBRA em qualquer utilização. Ficam reservados exclusivamente ao(s) AUTOR(es) e/ou TITULAR(es) os usos comerciais da OBRA incluída no âmbito deste instrumento.

6. AUTORIA E TITULARIDADE - O AUTOR declara ainda que a obra é criação original própria e inédita, responsabilizando-se integralmente pelo conteúdo e outros elementos que fazem parte da OBRA, inclusive os direitos de voz e imagem vinculados à OBRA, obrigando-se a indenizar terceiros por danos, bem como indenizar e ressarcir a FIOCRUZ - FUNDAÇÃO OSWALDO CRUZ de eventuais despesas que vierem a suportar, em razão de qualquer ofensa a direitos autorais ou direitos de voz ou imagem, principalmente no que diz respeito a plágio e violações de direitos.

7. GRATUIDADE - A cessão e autorização dos direitos indicados e estabelecidos neste Instrumento será gratuita, não sendo devida qualquer remuneração, a qualquer título, ao autor e/ou titular, a qualquer tempo.

Report an error